

Please amend claim 3, 5, 7, 11, 33 and 35 as follows. A copy of all pending claims accompanies this Response.

A2  
1. (Amended) A recombinant antibody capable of specifically binding to SAGA-1, said antibody comprising an antigen-binding region of the S19 monoclonal antibody, wherein the antigen-binding region consists essentially of SEQ ID NO: 1 and SEQ ID NO: 3 bound to one another by a linker [two peptide fragments of monoclonal antibody S19, or peptide mimetics thereof, wherein said fragments are covalently linked together by a linker, and said recombinant antibody containing less than 30% of the native S19 protein sequences].

A3  
3. (Amended) The recombinant antibody of claim 2 wherein the peptide linker is a (Gly<sub>4</sub>Ser)<sub>n</sub> polymer, wherein n is an integer ranging from 1-6 [5-20 amino acids in length].

A4  
5. (Amended) The recombinant monoclonal antibody of claim [4] 3 wherein the recombinant monoclonal antibody is coupled to an effector molecule selected from the group consisting of toxins, virucides and microbicides.

A5  
7. (Amended) The recombinant monoclonal antibody of claim [4] 3 wherein the recombinant monoclonal antibody is coupled to a diagnostic label.

A6  
11. (Amended) The composition of claim 9, wherein said recombinant monoclonal [antibodies are] antibody is present on the surface of liposomes.

A7  
33. (Amended) A nucleic acid sequence comprising a single chain Fv fragment selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 16 and SEQ ID NO: 12.

A8  
35. (Amended) A host cell comprising heterologous DNA encoding a single chain Fv fragment selected from the group consisting of SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 17 and SEQ ID NO: 12.